Philip Morris International (PMI) this week submitted its iQOS technology for approval as a reduced-risk product by the U.S. Food and Drug Administration (FDA), a strategy which if successful would provide a tremendous boost to the credibility of heat-not-burn and perhaps pave the way for PMI’s partner Altria to dominate that market in the United States. ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section